Abstract: Delivery of chemotherapeutic drugs to tumours by reformulation as nanoparticles has often been proposed as a means of facilitating increased selective uptake, exploiting the increased permeability of the tumour vasculature. However realisation of this improvement in drug delivery in cancer patients has met with limited success. We have compared tumour uptake of soluble Tc99m-pertechnetate and a colloid of nanoparticles with a Tc99m core, using both intravenous and intraarterial routes of administration in a rabbit liver VX2 tumour model. The radiolabelled nanoparticles were tested both in untreated and cationised form. The results from this tumour model in an internal organ show a marked advantage in intra-arterial administration over the intravenous route, even for the soluble isotope. Tumour accumulation of nanoparticles from arterial administration was augmented by cationisation of the nanoparticle surface with histone proteins, which consistently facilitated selective accumulation within microvessels at the periphery of tumours. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Abstract:
Abstract:
Delivery of chemotherapeutic drugs to tumours by reformulation as nanoparticles has often been proposed as a means of facilitating increased selective uptake, exploiting the increased permeability of the tumour vasculature. However realisation of this improvement in drug delivery in cancer patients has met with limited success. We have compared tumour uptake of soluble Tc99m-pertechnetate and a colloid of nanoparticles with a Tc99m core, using both intravenous and intraarterial routes of administration in a rabbit liver VX2 tumour model. The radiolabelled nanoparticles were tested both in untreated and cationised form. The results from this tumour model in an internal organ show a marked advantage in intra-arterial administration over the intravenous route, even for the soluble isotope. Tumour accumulation of nanoparticles from arterial administration was augmented by cationisation of the nanoparticle surface with histone proteins, which consistently facilitated selective accumulation within microvessels at the periphery of tumours.
Keywords: Nanoparticle delivery, arterial administration, vascular permeability, imaging isotope, liver cancer. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60
Introduction
The growth of a tumour in a host organ is accompanied by angiogenesis that not only markedly changes the architecture of the vascular network [1] [2] [3] , but also considerably increases access to the extravascular space due to the increased permeability of the new vessels [4] . This provides opportunity for improvement in delivery of chemotherapeutic agents by reformulation into nanoparticulate composites that can extravasate into tumours [5] .
Nanoparticles tend to be rapidly removed from the circulation by the phagocytic cells resident in the liver and spleen (reticuloendothelial system; RES), but it has been suggested they can also escape through the highly fenestrated walls of tumour capillaries and distribute within the tumour matrix [6] . Extravasation of macromolecules into tumours has been known for many years, visualised earlier for example by increased dye uptake [7] , and this has become known as the enhanced permeability and retention (EPR) effect [8] . Thus it is the object of much current research to exploit tumour EPR by administration of nanoparticulate formulations of cytotoxic agents [9, 10] . It should be noted however that while most preclinical studies have been done in animal models of subcutaneously implanted tumours, data on extravasation, penetration and accumulation of nanoparticles in tumours of internal organs, like many of those cancers occurring in human patients, is especially lacking. In this context, it is also important to explore different routes of administration, especially intra-arterial instillation.
In this report we have investigated tumour uptake of imaging radioisotope in the form of a soluble compound (Tc99m-pertechnetate) and compared this with uptake of a nanoparticulate isotope preparation. Further, we have performed these imaging investigations in a rabbit tumour model of liver cancer, where we could study biodistribution inside this internal organ after intra-venous and intra-arterial administration of both types of agents . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Materials and Methods:
Nanoparticle synthesis
Carbon-caged Tc-99m, (FibrinLite; FL) was synthesised as described in detail in US patent 8,778,300 [11] . The nanoparticle technology employed was based on Technegas™, a radioactive aerosol preparation developed for diagnostic ventilation imaging of the lungs [12] .
Vapour-phase particle sizing using an electrostatic particle classifier (TSI Inc, MN USA)
showed the aerosol comprises log-normal distributed particles with the bell curve centred on 150-350 nm, and negligible particles below 100 nm or above 400 nm. Electron microscope characterisation shows metallic platelets surrounded by multiple lamellae of carbon [13] .
Using the patented FL process, sodium Tc99m-pertechnetate solution was loaded into a graphite crucible and after removing sodium chloride by sublimation at 1650ºC, the isotope was plasma ablated at 2750ºC into an argon gas stream. Aerosol nanoparticles were collected into water (6.0 mL) from the gas stream using a Browitt sonicating precipitator [14] , thus producing a stable colloidal dispersion of FL. The radioactive FL colloid was filtered through a 450 nm hydrophilic membrane (mixed cellulose ester (MCE); Millipore) before use.
A typical preparation of FL contained approximately 5 µg/mL of graphitic carbon with a specific activity of 20 MBq/µg. FL nanoparticles are highly stable, and integrity of the isotope encapsulation is preserved under standard autoclave conditions of 20 min at 120ºC.
Coating of FL with polycations
We have previously shown using a membrane filtration model and microwell binding assays that polycations such as polylysine bind to the surface of FL with high affinity [15] . We have proposed [15] that this is mediated by multi-site pi-cation interactions [16, 17] between the positively charged amino groups of the amino acid side-chains and the pi-electrons of the planar carbon rings of the graphite surface. The histone family of proteins are also polycations due to a high content of arginine and lysine residues [18] and binding of these proteins to FL can only be reversed with strong ionic detergents such as sodium dodecyl sulfate [19] . blood flow, so as to disperse the isotope throughout the liver with close to normal blood perfusion conditions [21] . Symporter uptake of pertechnetate in organs and tumours was tested for by prior intravenous injection of sodium perchlorate (3 mg/kg; Sigma Aldrich) [22] .
Heparan sulphate mediated endothelial uptake of cationised FL was tested for by prior intravenous injection of competing polyions [19] : PS (1 mg/kg), PDL (1 mg/kg), and heparin (1 mg/kg; Sigma Aldrich), or by prior treatment of the rabbit for 1 h with intravenous injection of heparinase type III (10 units; Sigma Aldrich) [19] .
Static 5 min acquisitions were made on a 1024 x 1024 matrix approx 10 min after administration of the imaging agent and again after one hour. After completion of imaging, the rabbit was euthanized by lethal injection while still under anaesthesia, and the liver was excised after tying off all vessels to prevent leakage of isotope. The excised liver was then imaged separately using a 5 min acquisition on a 1024 x 1024 matrix, and utilising a zoom function (e.g. 3.2x or 4x). Counts registered in the acquisitions were corrected for the background activity of the corresponding field, and the corrected counts were used for calculation of the percentage activity in the liver compared to the carcass. Tumour uptake data was limited to tumours that had grown to at least 1.0 cm 3 and located in the same lobe of the liver in each rabbit. Activity levels in the images shown in the Figures were assigned false colours using the A2 colours in the Siemens Diacam gamma camera or the XT21 Brain1 colours in the Hawkeye Infinia SPECT/CT colour maps respectively. Results
Biodistribution of soluble Tc99m-Pertechnetate
Intravenous injection of soluble Tc99m-pertechnetate produced images of circulating radioactivity distributed according to the blood perfusion of the main organs (heart, lungs, liver and spleen) but also with some accumulation in the kidneys and thyroid at 1 h post-injection ( Fig 1A) . The excised liver 1 h post-injection retained only 15.8% of the total radioactivity (see Table 1 ) and the gamma camera image showed it was generally dispersed throughout the lobes of the organ. When Tc99m-pertechnetate was instilled in the hepatic artery, again only 14.5% of the activity was found in the liver after 1 h (Table 1) , and the systemic distribution of label was not distinguishable from that obtained with intravenous injection of pertechnetate.
Intravenous injection of Tc99m-pertechnetate into rabbits bearing VX2 implants in their livers produced images with a noticeable shadow (isotope deficit) at the site of the tumour implant compared to the rest of the liver (Fig 1B) . Retention of Tc99m-pertechnetate label by the liver hosting a tumour was similar to a normal liver; 12.3% of the total radioactivity at 1 h post injection (Table 1) .
By contrast, hepatic artery instillation of Tc99m-pertechnetate into rabbits hosting a VX2 liver tumour showed in all cases (n = 7) a prominent focal area of radioactivity in the liver persisting through to at least 1 h post instillation (Fig 1C) , so that on excising the liver and imaging separately the percentage of total activity retained in the liver was clearly higher than in normal rabbits (26.4%; see Table 1 ). Furthermore there was a considerable accumulation of radiolabel in the tumour ( Fig 1D) ; 28.9% of the isotope retained by the whole liver (Table 1) , as estimated by applying a region of interest to the image, which usually results in an underestimate. Since pertechnetate can potentially be internalised in cells by the expression of a membrane transport system known as the sodium iodide symporter (NIS), we tested the effect of prior intravenous administration of sodium perchlorate as a specific competitive inhibitor [22] . Preadministration of perchlorate strongly attenuated thyroid uptake of Tc-99m-pertechnetate but only partially affected liver tumour uptake (Table 1) and did not prevent clear definition of liver tumours in imaging (see Fig 1E) . Since polycations have been shown to increase vascular permeability in the lungs [23] , we also tested the effect of intra-hepatic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 artery instillation of PDL (150 µg) 15 min before instilling the Tc99m-pertechnetate in the same catheter; this pretreatment did not increase the retention of label in the liver or the tumour (not shown).
Biodistribution of colloidal FL
Intravenous injection of untreated FL showed rapid uptake and concentration in the reticuloendothelial system (liver, spleen and bone marrow; RES) as reported previously [15] .
Imaging of the excised liver at 1 h post injection showed that the accumulated radioactivity was generally dispersed throughout the lobes of the organ, and accounted for approximately 80% of the total radioactivity administered ( Table 2 ). This figure was higher than our previous estimate of 60% made using a region of interest on the liver image in the intact animal [15] .
When FL was administered by hepatic artery instillation, the whole body image and excised liver image were closely similar to those obtained after intravenous injection of FL, but the isotope activity retained in the liver at excision 1 h post instillation was higher, over 90% of the total dose administered ( Table 2 ).
Intravenous injection of untreated FL into rabbits bearing VX2 implants in their livers
showed rapid uptake of label by the liver as in normal rabbits, but on imaging the excised liver at 1 h post injection it was evident that there was a noticeable shadow (isotope deficit) at the site of the tumour implant compared to the rest of the liver (Figs 2A,B) . When the FL was instilled via the hepatic artery, liver uptake was as strong as seen in a normal liver (93.7%; Table 2 ). In 2 out of 5 of these cases there was a noticeable arc of activity proximal to the main arterial entry or even a complete ring of activity around the site of the tumour, but these features did not have a remarkably higher count per pixel than some other normal areas of the same liver ( Figs 2C,D) .
Biodistribution of cationised colloidal FL
It has been suggested that nanoparticles with a positively charged surface are more readily taken up by endothelium in the vasculature of a tumour [24, 25] . Thus we tested the effect of cationising FL on its uptake into livers and liver tumours following hepatic artery instillation. FL was cationised with surface coatings of PS, PDL and CTH [15, 19] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 These surface coatings did not change the strong liver retention of nanoparticles after arterial instillation (Table 2) . Increased tumour uptake of nanoparticles was seen in a minority of cases after coating with PS and PDL (3 out of 10 cases), but this could have been merely due to larger tumour size; a detailed study was not done. However coating with CTH consistently produced a pronounced increase in tumour uptake of isotope, so that the tumour was often readily visible on imaging of the intact animal ( Fig 3A) and in every case (n=8) featured prominently in the excised liver (Fig 3B) . Radiolabel was consistently concentrated at the periphery of tumours, sometimes appearing as a continuous bright ring encircling the actual tumour mass (Fig 3B) . Of the different liver tumour imaging methods tested in this study, intra-arterial administration of CTH coated FL produced the highest proportion of the administered dose accumulated at tumour sites (17.5%; Table 3 ), while 95% of the total administered dose was still retained by the host liver.
Since marked accumulation of CTH/FL at tumour sites was evident in gamma camera imaging, we investigated further at the histological level. In standard haematoxylin and eosin stained sections, it was not possible to find any carbon particles after hepatic artery installation of uncoated FL, even at high power magnification; the uniform distribution of the microgram quantities of nanoparticles into the rabbit livers (mean weight 117 g; n=23)
produced dilution to the point where they were not detectable. By contrast, CTH/FL that was strongly accumulated in liver tumours as seen by gamma camera imaging (Fig 3B) , could also be found on microscopic examination of sections from the same liver (Fig 3C) . Clusters of black carbon particles were clearly visible accumulated in microvessels located in close proximity to the edge of the tumour, but were absent in vessels further away from the tumour, or within the nests of tumour cells (Fig 3C) . In some cases extravascular macrophages contained some carbon particles, but it was clear that the majority of nanoparticles accumulated in intravascular clusters without extravasation.
The mechanism responsible for the liver tumour accumulation of CTH/FL was investigated using similar inhibition methods to those we previously used in lung perfusion studies [15, 19] . Unlike accumulation of CTH/FL on heparan sulphate in the capillary network of normal rabbit lungs, the uptake of CTH/FL in rabbit VX2 liver tumours was not abolished by prior intravenous injection of potentially competing polycations; tumours were still clearly 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 visible in livers from rabbits that had been preinjected with PS ( Fig 4A) and PDL (Fig 4B) , and the tumours were also still labelled following pretreatment of the rabbit with intravenous heparinase [19] (not shown). Labelling of tumour was also still clearly evident even when the CTH/FL preparation was treated with heparin in vitro prior to intra-arterial instillation (Fig 4C) .
The percentage of CTH/FL label present at tumour sites in all of these inhibition tests was not outside the range for the tumours in Table 3.   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Discussion A detailed study of the liver uptake of soluble Tc-99m pertechnetate and Tc99m radiolabelled nanoparticles (FL) was made in rabbits following administration by both intravenous and intra-arterial (common hepatic artery) routes. Uptake from this set of administrations in normal rabbits was then compared with the uptake obtained after administration to rabbits bearing a model liver tumour, the transplantable rabbit VX2
carcinoma. This provided data for each form of the radiolabel on the accumulation within the liver compared to the systemic distribution, and on the uptake of label by a tumour compared to the normal liver tissue of the host.
While soluble Tc-99m as pertechnetate was widely distributed in the body following intravenous injection, with some accumulation in the thyroid and kidneys, FL was rapidly taken up by the reticuloendothelial system, as shown previously [15] . In rabbits hosting a liver VX2 implant, there were notable differences when pertechnetate and FL were administered arterially; pertechnetate showed unexpectedly high and persistent signal in the tumour, presumably due to the highly fenestrated new arterial vessels produced during tumour angiogenesis under the influence of tumour cytokines [26] .
Active uptake of pertechnetate has been noted before in other tumours [27, 28] , where it has been shown to be due to endogenous iodide symporter (NIS) expression, but in the case of VX2 liver tumours we found that while a competitive inhibitor of the NIS (perchlorate)
prevented uptake of pertechnetate in the thyroid, it did not prevent pertechnetate uptake by the VX2 tumour in the liver. Permeability of the liver arterial system to pertechnetate was unaffected by PDL, unlike the increase in permeability induced in the lungs by polycations,
shown by Dull et al [23] to be mediated by endothelial heparan sulphate.
Arterial administration of FL showed some concentration of label around the tumour site in a minority of cases, presumably also due to the increased vascularity following angiogenesis, but this was not as consistent or pronounced as in the case of pertechnetate ,   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 suggesting the nanoparticles may be too large to extravasate [29] . However when the FL was surface cationised by CTH, there was a consistent and marked increase in accumulation at the tumour site. In at least two cases this accumulation was visible both in gamma camera imaging as well as in histology, when accumulations of black carbon were found inside microvessels close to the edge of tumour cell nests, but not in vessels further away.
Since accumulation of CTH/FL at liver tumours was not affected by prior treatment of the host rabbits with PDL or heparinase, or even by treatment of the CTH/FL with heparin in vitro prior to intra-arterial instillation, it appears that the mechanism involved is not a simple charge interaction with endothelial heparan sulphate as we found previously in the lungs [15, 19] . Significantly, there was also no effect on liver tumour accumulation of CTH/FL when the host was pretreated with PS. These observations together suggest that a more specific interaction of CTH is involved, since the protamines are a very similar group of cationic nuclear proteins to histones. One possibility would be that CTH is binding to Toll-like receptors on the angiogenic endothelium induced by cytokines at tumour sites [30] . The results also showed that accumulation of nanoparticles at a tumour site does not necessarily imply extravasation has occurred; at histology we found accumulation of CTH/FL within microvessels at the edge of liver tumours but not outside microvessels or within the nests of tumour cells. Clearly this has significant implications not only for delivery of cytotoxic drugs to tumour cells but also for tumour cell targeting dependent on monoclonal antibody coated nanoparticles actually reaching their cognate target antigens on tumour cells. The data instead supports the notion that targeting of angiogenic endothelium at tumour sites is a more attractive strategy .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65
Conclusion
Our results with a model tumour system hosted in an internal organ provide useful insight into the tissue penetration of different isotope preparations following administration by the intravenous and intra-arterial routes, further illustrating the difference in tumour accessibility. Uptake of soluble pertechnetate and FL nanoparticles into tumours from the venous circulation was uniformly absent, whereas both preparations were accumulated in the immediate periphery of liver tumours following intra-arterial instillation, even despite their large difference in size. Effective dosing of liver tumours with a nanoparticle agent is thus shown to have considerably more chance of success when administered by the arterial route*.
Our isotope imaging and histological findings with histone-coated nanoparticles further suggest that this formulation can specifically accumulate nanoparticles in angiogenic microvessels at the growth zone peripheral to tumours.
*Footnote: During preparation of this manuscript some similar findings were reported by Tian et al [31] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65 in the intact rabbit in Fig 1C, and in the excised liver from Fig 1C shown in Fig 1D. Positive imaging of the tumour in a rabbit by intra-arterial Tc99m-pertechnetate was not abolished (V in Fig 1E) by prior intravenous injection of sodium perchlorate (3 mg/kg), an inhibitor of the active transport of iodide and pertechnetate [22] . Images were acquired with a GE Hawkeye Infinia gamma camera. (Fig 4A) and poly-D-lysine (1 mg/kg) (Fig 4B) , 10 min prior to intra-arterial instillation of CTH/ FL (5 mL, 130 MBq). Note that tumours were labelled in each of these pretreated rabbits (tumours indicated by V). When the CTH/FL preparation was treated with heparin (1 mg/mL) in vitro before intra-arterial instillation, the tumour was still strongly labelled (Fig 4C) . Images in Figs 4A-C were acquired with a GE Hawkeye Infinia gamma camera. Tables   Table 1 Retention of radioisotope activity in the livers of normal rabbits and livers of rabbits hosting a VX2 implant, 1 h after administration of Tc99m-pertechnetate (130 MBq) by intravenous injection (3 mL; IV) or intra-arterial instillation (5 mL; IHA). Activity in the excised liver image was compared to the body image after removal of the liver, and corrected for background in the corresponding detection fields. For two tumour rabbits, sodium perchlorate (3 mg/kg) was injected intravenously before IHA instillation of the isotope, to test the role of symporter in tumour retention of pertechnetate [22] . Retention of radioisotope activity in the liver of normal rabbits and livers of rabbits hosting a VX2 implant, 1 h after administration of FL nanoparticles (130 MBq) by intravenous injection (3 mL; IV) or intra-arterial instillation (5 mL; IHA). Activity in the excised liver image was compared to the body image after removal of the liver, and corrected for background in the corresponding detection fields. FL was tested either untreated or surface cationised with protamine sulphate (PS), poly-D-lysine (PDL) or calf thymus histones (CTH). 
